시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 섬유아세포 활성화 단백질 억제제 시장 보고서(2025년)
Fibroblast Activation Protein Inhibitors Global Market Report 2025
상품코드 : 1764316
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,292,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,095,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,897,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

섬유아세포 활성화 단백질 억제제 시장 규모는 향후 수년간 강력한 성장이 전망될 예정입니다. 예측 기간 동안의 성장은 섬유아세포 활성화 단백질(FAP) 억제제의 파이프라인 확대, 비암 질환에서의 적용 범위 확대, 복합 요법 사용 증가, 암 연구에 대한 정부 자금 지원 증가, 제약사의 관심 증가 등에 기인할 것으로 분석됩니다. 이 기간 동안 예상되는 주요 동향으로는 표적 의약품 전달 시스템의 발전, 차세대 FAP 억제제 개발, 동반 진단 기술의 혁신, 면역요법 병용 전략의 발전, 환자 순응도를 높이기 위한 경구 투여 옵션의 제형 개발 등이 있습니다.

암 발병률의 증가는 향후 몇 년 동안 섬유아세포 활성화 단백질(FAP) 억제제 시장의 성장을 촉진할 것으로 예상됩니다. 암은 주변 조직을 침범하고 신체의 다른 부위로 전이될 수 있는 비정상적인 세포의 통제되지 않은 증식으로 특징지을 수 있으며, 다양한 조직에서 발생하고 그 기원의 세포 또는 조직에 따라 분류됩니다. 암 발병 건수의 증가는 인구 고령화, 생활 습관 변화, 환경 노출, 진단 방법의 개선 등 여러 요인에 기인합니다. FAP 억제제는 종양을 지지하는 섬유모세포를 표적으로 하는 종양학에서 사용되어 진단 영상 및 암 치료의 전달을 모두 향상시킵니다. 예를 들어, 2024년 8월 영국 기반 자선 단체인 맥밀란 암 지원(Macmillan Cancer Support)은 2024년 영국에서 암을 앓고 있는 사람이 300만 명을 넘었으며, 이 숫자가 2025년 350만 명, 2030년 400만 명, 2040년 530만 명으로 증가할 것으로 전망했습니다. 이로 인해 암 발생률의 증가가 FAP 억제제 시장 확장을 촉진하고 있습니다.

FAP 억제제 시장 선도 기업들은 방사성 의약품 전달의 정밀도를 높이고 진단 영상 정확도를 개선하며 암 치료의 치료 효과를 향상시키기 위해 SAR 킬레이터 기술을 FAP 표적화와 결합하는 것을 increasingly 도입하고 있습니다. SAR 킬레이트 기술은 방사성 금속을 안전하게 결합하는 특수 분자를 사용하여 연구자들이 구조적 변화가 의약품의 성능에 미치는 영향을 평가할 수 있도록 합니다. 이 기술은 주로 영상 진단이나 치료 목적으로 방사성 물질을 암세포로 직접 유도하는 데 사용됩니다. 예를 들어, 2024년 12월, 호주에 본사를 둔 방사성 의약품 회사인 Clarity Pharmaceuticals는 정밀 종양학을 위해 개발된 첨단 치료제인 혁신적인 FAP 표적 방사성 의약품을 출시했습니다. 이 새로운 약물은 Clarity의 임상 파이프라인을 확장하며, FAP 발현이 높은 암에 대한 고도로 선택적인 치료 옵션을 제공하며, 진단 명확성과 치료 효과를 모두 향상시킬 잠재력을 가지고 있습니다. 이 성과는 Clarity가 개인화 암 치료를 지원하는 방사성 의약품 개발에 대한 지속적인 헌신을 반영합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 19 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별, 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

HBR
영문 목차

영문목차

Fibroblast activation protein (FAP) inhibitors are targeted therapies used to treat fibrosis-related conditions by blocking the activity of FAP, a protein involved in tissue scarring. As small-molecule inhibitors, they work by specifically inhibiting FAP to reduce the formation of excess fibrous tissue, thereby helping to preserve or improve organ function by slowing the progression of fibrosis.

The primary types of fibroblast activation protein inhibitors include small molecule inhibitors, monoclonal antibodies, and peptide inhibitors. Small molecule inhibitors are low molecular weight compounds that can effectively penetrate cells to inhibit FAP's enzymatic activity. These inhibitors are being investigated for various conditions such as interstitial cystitis, Crohn's disease, irritable bowel syndrome, chronic prostatitis, and others. They can be administered through different routes, including oral, intravenous, and subcutaneous methods. Distribution channels include hospital pharmacies, online pharmacies, and retail pharmacies, with use spanning multiple healthcare settings such as hospitals, homecare, specialty clinics, and more.

The fibroblast activation protein inhibitors market research report is one of a series of new reports from The Business Research Company that provides fibroblast activation protein inhibitors market statistics, including the fibroblast activation protein inhibitors industry global market size, regional shares, competitors with the fibroblast activation protein inhibitors market share, detailed fibroblast activation protein inhibitors market segments, market trends, and opportunities, and any further data you may need to thrive in the fibroblast activation protein inhibitors industry. This fibroblast activation protein inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The fibroblast activation protein inhibitors market size has grown rapidly in recent years. It will grow from $2.74 billion in 2024 to $3.02 billion in 2025 at a compound annual growth rate (CAGR) of 10.0%. Growth during the historic period can be attributed to the growing emphasis on personalized medicine, increased investment in oncology drug discovery, the advancement of biomarker-based drug development, expanding collaboration among biotechnology companies, and heightened interest in targeting the tumor stroma as a therapeutic approach.

The fibroblast activation protein inhibitors market size is expected to see strong growth in the next few years. It will grow to $4.37 billion in 2029 at a compound annual growth rate (CAGR) of 9.7%. Growth in the forecast period can be attributed to the expanding pipeline of fibroblast activation protein (FAP) inhibitors, broader applications in non-oncology conditions, increasing use of combination therapies, rising government funding for cancer research, and growing interest from pharmaceutical companies. Key trends expected during this period include advancements in targeted drug delivery systems, the development of next-generation FAP inhibitors, innovation in companion diagnostic technologies, progress in immunotherapy combination strategies, and the formulation of oral delivery options to enhance patient compliance.

The rising incidence of cancer is expected to drive the growth of the fibroblast activation protein (FAP) inhibitors market in the coming years. Cancer is characterized by the uncontrolled growth of abnormal cells that can invade surrounding tissues and spread to other parts of the body, originating in various tissues and classified based on their cell or tissue of origin. The growing number of cancer cases is attributed to factors such as aging populations, lifestyle changes, environmental exposures, and improvements in diagnostic methods. FAP inhibitors are used in oncology to target tumor-supporting fibroblasts, thereby enhancing both diagnostic imaging and the delivery of cancer therapies. For example, in August 2024, Macmillan Cancer Support, a UK-based charitable organization, reported that over 3 million people in the UK were living with cancer in 2024, with projections indicating this number will rise to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Consequently, the increasing incidence of cancer is fueling the expansion of the FAP inhibitors market.

Leading companies in the fibroblast activation protein (FAP) inhibitors market are increasingly incorporating SAR chelator technology with FAP targeting to enhance the precision of radiopharmaceutical delivery, improve diagnostic imaging accuracy, and boost therapeutic effectiveness in cancer treatment. SAR chelator technology involves the use of specialized molecules that securely bind radioactive metals, enabling researchers to assess how structural changes influence drug performance. This technology is primarily applied to guide radioactive agents directly to cancer cells for imaging or therapeutic purposes. For example, in December 2024, Clarity Pharmaceuticals, an Australia-based radiopharmaceutical company, introduced its innovative FAP-targeted radiopharmaceutical-an advanced therapy developed for precision oncology. This novel agent broadens Clarity's clinical pipeline and provides a highly selective treatment option for cancers exhibiting elevated FAP expression, with the potential to enhance both diagnostic clarity and treatment efficacy. This milestone reflects Clarity's ongoing commitment to developing radiopharmaceuticals that support personalized cancer care.

In March 2025, Telix Pharmaceuticals Ltd., an Australia-based radiopharmaceutical company, acquired a portfolio of fibroblast activation protein (FAP)-targeting theranostic radiopharmaceutical candidates developed by Professor Frank Rosch and his team at Johannes Gutenberg University Mainz. The financial terms of the deal were not disclosed. This acquisition is intended to leverage Telix's global commercial capabilities and expertise in theranostics to accelerate the development of FAP-targeting agents. The acquired portfolio includes both preclinical and clinical-stage candidates designed for the imaging and treatment of various cancers. Johannes Gutenberg University Mainz, based in Germany, is recognized for its specialization in nuclear chemistry.

Major players in the fibroblast activation protein inhibitors market are Roche Ltd., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Teva Pharmaceutical Industries Ltd., Jazz Pharmaceuticals Inc., Prestige Consumer Healthcare Inc., SOFIE Biosciences Inc., Molecular Partners, FibroGen Inc., Elicio Therapeutics Inc., Huya Bioscience International, Agios Pharmaceuticals Inc., MedChemExpress, Boster Biological Technology, Nordic Nanovector, Ferronova, InvivoChem, PsiOxus Therapeutics, and Angion Biomedica Corp.

North America was the largest region in the fibroblast activation protein inhibitors market in 2024. The regions covered in fibroblast activation protein inhibitors report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the fibroblast activation protein inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The fibroblast activation protein inhibitors market consists of sales of antibody-drug conjugates, radiolabeled inhibitors, and combination therapies targeting fibroblast activation protein. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Fibroblast Activation Protein Inhibitors Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on fibroblast activation protein inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for fibroblast activation protein inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The fibroblast activation protein inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Fibroblast Activation Protein Inhibitors Market Characteristics

3. Fibroblast Activation Protein Inhibitors Market Trends And Strategies

4. Fibroblast Activation Protein Inhibitors Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Fibroblast Activation Protein Inhibitors Growth Analysis And Strategic Analysis Framework

6. Fibroblast Activation Protein Inhibitors Market Segmentation

7. Fibroblast Activation Protein Inhibitors Market Regional And Country Analysis

8. Asia-Pacific Fibroblast Activation Protein Inhibitors Market

9. China Fibroblast Activation Protein Inhibitors Market

10. India Fibroblast Activation Protein Inhibitors Market

11. Japan Fibroblast Activation Protein Inhibitors Market

12. Australia Fibroblast Activation Protein Inhibitors Market

13. Indonesia Fibroblast Activation Protein Inhibitors Market

14. South Korea Fibroblast Activation Protein Inhibitors Market

15. Western Europe Fibroblast Activation Protein Inhibitors Market

16. UK Fibroblast Activation Protein Inhibitors Market

17. Germany Fibroblast Activation Protein Inhibitors Market

18. France Fibroblast Activation Protein Inhibitors Market

19. Italy Fibroblast Activation Protein Inhibitors Market

20. Spain Fibroblast Activation Protein Inhibitors Market

21. Eastern Europe Fibroblast Activation Protein Inhibitors Market

22. Russia Fibroblast Activation Protein Inhibitors Market

23. North America Fibroblast Activation Protein Inhibitors Market

24. USA Fibroblast Activation Protein Inhibitors Market

25. Canada Fibroblast Activation Protein Inhibitors Market

26. South America Fibroblast Activation Protein Inhibitors Market

27. Brazil Fibroblast Activation Protein Inhibitors Market

28. Middle East Fibroblast Activation Protein Inhibitors Market

29. Africa Fibroblast Activation Protein Inhibitors Market

30. Fibroblast Activation Protein Inhibitors Market Competitive Landscape And Company Profiles

31. Fibroblast Activation Protein Inhibitors Market Other Major And Innovative Companies

32. Global Fibroblast Activation Protein Inhibitors Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Fibroblast Activation Protein Inhibitors Market

34. Recent Developments In The Fibroblast Activation Protein Inhibitors Market

35. Fibroblast Activation Protein Inhibitors Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기